IPS Therapeutique (IPST) is a Contract Research Organization dedicated to the preclinical evaluation of the efficacy and safety of new drugs using validated and highly predictive models – with a strong cardiovascular focus. IPST believes each study is worthy of tailored protocols designed to maximize the scientific and strategic value of the data generated.
We believe in taking ownership of the studies entrusted to us while ensuring mutual collaboration for developing and agreeing to overall project plans.
Established in 1999, we have conducted more than 650 preclinical cardiac safety and efficacy studies and over 100 GLP-compliant studies in support of FDA, EMEA, Health Canada and the Japanese MoHW. This is in addition to unique, long-term development programs spanning years with over a dozen large pharmaceutical companies, who rely on IPST for its expertise, its efficiency, and its flexibility when running challening, unique experiments. IPST’s stellar reputation may be the small pharma world’s best-kept secret; IPST consistently delivers accurate results at a reasonable cost, on time. IPST is proud of its applied science approach to addressing the needs of both start-up and mature biopharmaceutical and nutraceutical companies.
IPST does not sell pharmaceutical services: we sell accurate answers to unique challenges in drug development.